Skip to main content
TipRanks
Go Ultimate75% OFF

Penumbra (PEN) AI Stock Analysis

481 Followers
PEN

Penumbra

(NYSE:PEN)

Select Model
Rating:67Neutral
Price Target:$349.00â–²(8.75% Upside)
Action:downgraded
Date:10/30/26

The score is primarily supported by strong financial performance—rapid revenue growth into TTM, solid profitability, healthy cash generation, and low leverage. The rating is held back by expensive valuation (high P/E) and mixed technical positioning, including trading below the 200-day moving average.

Positive Factors
Revenue and Profitability GrowthPenumbra is combining rapid revenue expansion with healthy gross and operating profitability, showing that growth is translating into earnings rather than relying solely on volume. This creates greater internal capacity to invest in products, commercial reach, and clinical adoption over the coming quarters.
Negative Factors
Margin CompressionDeclining net margins indicate that higher revenue is not converting into proportionally higher profitability. Whether driven by costs, product mix, or reinvestment, sustained compression could limit earnings scalability and reduce the financial benefit of otherwise strong growth over the next several quarters.

Penumbra (PEN) vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%25%30%PEN+15.39%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$12.65B
Dividend Yield
―
Average Volume (3M)
355.03K
Price to Earnings (P/E)
80.4
Beta (1Y)
0.03
Revenue Growth
16.98%
EPS Growth
-5.62%
Country
US
Employees
4,700
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Penumbra Business Overview & Revenue Model

Company Description

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the In...

How the Company Makes Money

Penumbra makes money primarily by selling medical devices and single-use consumables used in interventional procedures. The company’s revenue model is largely product-driven: hospitals and healthcare providers purchase Penumbra’s thrombectomy and int...

Penumbra Earnings Call Summary

Earnings Call Date:Nov 05, 2025(Q3-2025)|% Change Since:42.29%|Next Earnings Date:Feb 23, 2027
Earnings Call SentimentPositive

The earnings call reflected a strong performance with significant revenue growth, particularly in the VTE and embolization segments, and positive developments in clinical trials, offset by some challenges in international markets and increased operational costs.

Positive Updates

Strong Revenue Growth
Total revenue reached $354.7 million, showing a year-over-year growth of 17.8% on a reported basis and 16.9% in constant currency. U.S. revenue grew by 21.5% to $275 million.

Negative Updates

China Growth Headwinds
Continued growth headwinds in China, though international revenue still increased by 6.6% year-over-year.

Company Guidance

During Penumbra's third-quarter 2025 conference call, the company reported total revenue of $354.7 million, marking a 17.8% year-over-year growth on a reported basis and 16.9% in constant currency. U.S. revenue reached $275 million, a 21.5% increase compared to the previous year. Specifically, U.S. thrombectomy sales rose by 18.5% to $192 million, while the VTE franchise led corporate growth with a 34% rise. Meanwhile, U.S. embolization and access revenue soared by 29.2% to $83 million. International revenue was $79.7 million, reflecting a 6.6% year-over-year increase. The company's gross margin expanded by 130 basis points to 67.8%, and operating income stood at $48.8 million, or 13.8% of revenue. Penumbra's guidance for the year was raised to $1.375 billion to $1.380 billion in revenue, with anticipated U.S. thrombectomy growth of 20% to 21% for 2025. The company remains focused on expanding its market presence, particularly through innovative products like the Lightning Bolt 16 and Lightning Flash 3.0, which have received FDA clearance.

Penumbra Financial Statement Overview

Summary

Strong revenue acceleration into TTM alongside robust gross margin (~68%) and improved profitability (TTM operating margin ~9.8%, net margin ~10.1%). Balance sheet is conservatively levered (TTM debt-to-equity ~0.13) with growing equity, and cash conversion is solid (operating cash flow ~1.19x net income). Key offsets are margin compression versus 2025 and a recent decline in free cash flow (TTM FCF down ~7.2% YoY).

Income Statement

78Positive

Balance Sheet

86Very Positive

Cash Flow

74Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.56B1.40B1.19B1.06B847.13M747.59M
Gross Profit1.06B942.44M755.00M682.64M535.21M475.38M
EBITDA229.21M223.91M45.99M108.65M29.96M7.84M
Net Income157.02M177.69M14.01M90.95M-2.00M5.28M
Balance Sheet
Total Assets2.03B1.83B1.53B1.56B1.37B1.24B
Cash, Cash Equivalents and Short-Term Investments673.61M544.82M340.13M289.19M188.03M254.88M
Total Debt209.39M219.70M223.39M234.34M235.77M173.55M
Total Liabilities441.59M398.92M382.25M377.36M372.03M290.32M
Stockholders Equity1.58B1.43B1.15B1.18B998.86M953.93M
Cash Flow
Free Cash Flow200.29M174.93M147.30M82.12M-74.96M-11.68M
Operating Cash Flow261.05M238.66M168.48M97.33M-55.66M9.50M
Investing Cash Flow-338.69M-404.59M77.62M-16.08M54.79M-21.73M
Financing Cash Flow11.12M26.53M-87.01M16.20M11.62M836.00K

Penumbra Technical Analysis

Technical Analysis SentimentNegative
Last Price320.91

Price Trends

50DMA320.15Positive
100DMA320.60Positive
200DMA325.71Negative

Market Momentum

MACD0.09Positive
RSI49.51Neutral
STOCH40.57Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PEN, the sentiment is Negative. The current price of 320.91 is below the 20-day moving average (MA) of 321.95, above the 50-day MA of 320.15, and below the 200-day MA of 325.71, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 49.51 is Neutral, neither overbought nor oversold. The STOCH value of 40.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PEN.

Penumbra Risk Analysis

Penumbra disclosed 64 risk factors in its most recent earnings report. Penumbra reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Because the market price of Boston Scientific Corporation common stock may fluctuate, holders of our common stock cannot be certain of the market value of the consideration they will receive in the Merger.Q4, 2025
2.Uncertainty associated with our agreement to be acquired by Boston Scientific Corporation could have an adverse effect on our business.Q4, 2025
3.The failure to complete the Merger could adversely affect our business.Q4, 2025

Penumbra Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PEN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MDTMDT81Outperform$131.58B25.1510.60%2.78%9.77%12.28%
SYKSYK75Outperform$117.88B32.7715.61%1.14%7.87%22.82%
ABTABT67Neutral$187.95B40.199.11%2.32%10.00%-66.06%
PHGPHG67Neutral$29.39B27.228.44%3.26%――
PENPEN67Neutral$12.65B80.4310.44%―16.98%-5.62%
BSXBSX64Neutral$64.27B18.7113.87%―8.88%25.77%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%20%PENABTBSXPHGMDTSYKDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PEN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PENPenumbra Inc.320.9142.4015.22%
ABTAbbott Laboratories108.52-18.36-14.47%
BSXBoston Scientific44.34-57.42-56.43%
PHGKoninklijke Philips N.V.30.343.2512.01%
MDTMedtronic102.869.6710.38%
SYKStryker Corp309.64-46.54-13.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026